Principle Wealth Partners LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.3% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,396 shares of the medical research company’s stock after selling 245 shares during the quarter. Principle Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $698,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Thermo Fisher Scientific by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 30,670,985 shares of the medical research company’s stock worth $9,007,455,000 after acquiring an additional 378,260 shares during the period. BlackRock Inc. boosted its holdings in Thermo Fisher Scientific by 1.4% in the 2nd quarter. BlackRock Inc. now owns 27,643,905 shares of the medical research company’s stock worth $8,118,461,000 after acquiring an additional 392,227 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Thermo Fisher Scientific by 2.4% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,139,325 shares of the medical research company’s stock worth $5,033,477,000 after acquiring an additional 395,830 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Thermo Fisher Scientific by 3.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,559,667 shares of the medical research company’s stock valued at $1,045,404,000 after buying an additional 102,504 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Thermo Fisher Scientific by 22.9% during the 2nd quarter. Janus Henderson Group PLC now owns 2,986,916 shares of the medical research company’s stock valued at $877,186,000 after buying an additional 555,802 shares during the last quarter. 88.24% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts have recently commented on the company. Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Monday, July 15th. Needham & Company LLC increased their target price on Thermo Fisher Scientific from $315.00 to $321.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Credit Suisse Group reiterated a “buy” rating and set a $310.00 target price on shares of Thermo Fisher Scientific in a research note on Wednesday, July 31st. ValuEngine cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Finally, JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $315.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, October 23rd. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $314.45.
NYSE TMO traded up $1.11 during trading hours on Friday, hitting $294.65. The company had a trading volume of 773,005 shares, compared to its average volume of 1,323,858. Thermo Fisher Scientific Inc. has a fifty-two week low of $208.34 and a fifty-two week high of $306.00. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56. The business has a fifty day simple moving average of $290.14 and a 200-day simple moving average of $283.57. The firm has a market cap of $117.34 billion, a P/E ratio of 26.50, a price-to-earnings-growth ratio of 1.90 and a beta of 1.14.
Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.88 by $0.06. Thermo Fisher Scientific had a return on equity of 17.16% and a net margin of 14.24%. The firm had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.19 billion. During the same period last year, the company earned $2.62 earnings per share. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 12.33 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Tuesday, December 17th will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 6.83%.
In other news, CEO Marc N. Casper sold 47,729 shares of the firm’s stock in a transaction on Friday, October 25th. The stock was sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the transaction, the chief executive officer now directly owns 328,960 shares of the company’s stock, valued at $97,332,684.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jim P. Manzi sold 1,833 shares of the firm’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $272.93, for a total value of $500,280.69. Following the transaction, the director now directly owns 28,592 shares in the company, valued at $7,803,614.56. The disclosure for this sale can be found here. Insiders have sold 51,833 shares of company stock worth $15,299,095 over the last three months. Corporate insiders own 0.45% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Article: What are the components of an earnings report?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.